Walleye Capital
CTMX icon

Walleye Capital’s CytomX Therapeutics CTMX Stock Holding History

Walleye Capital’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-85,638
Closed -$187K – 5658
2024
Q1 		$187K Buy
+85,638
New +$158K ﹤0.01% 4020
2022
Q2 		– Sell
-41,535
Closed -$111K – 2426
2022
Q1 		$111K Buy
+41,535
New +$159K ﹤0.01% 1717
2021
Q2 		– Sell
-17,345
Closed -$134 – 1369
2021
Q1 		$134 Buy
+17,345
New +$137K 0.01% 985
2020
Q1 		– Sell
-70,397
Closed -$585K – 1064
2019
Q4 		$585K Buy
+70,397
New +$475K 0.04% 607

Other funds holding CTMX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Walleye Capital's CTMX Position: Q2 2024 in Review

Walleye Capital sold out of CytomX Therapeutics (CTMX) in Q2 2024, closing a stake of 85,638 shares — an estimated $187K sold.

Walleye Capital first reported a position in CTMX in Q4 2019 and held it in 4 quarters. The position peaked at $585K in Q4 2019. 74 funds tracked by Wall St. Rank hold CTMX as of Q2 2024.

  • Walleye Capital reported no remaining CytomX Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Walleye Capital sold 85,638 CytomX Therapeutics shares in Q2 2024, an estimated $187K.
  • Walleye Capital first reported a position in CytomX Therapeutics in Q4 2019 and held it in 4 quarters.
  • Walleye Capital's CytomX Therapeutics position peaked at $585K in Q4 2019.
  • 74 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2024.

Based on Walleye Capital's 13F filing for Q2 2024, filed 14 Aug 2024.